EPICS: Global Perspectives in Lung Cancer – WCLC and ESMO 2021

Expert perspectives and strategic insights on the latest therapeutic developments and translational research coming out of ESMO and WCLC 2021 regarding lung cancer treatment.

September 24, 2021
Corey Langer MD Scientific Leader Faculty Chair Aptitude Health


Corey Langer, MD, FACP

University of Pennsylvania, Philadelphia, PA, US

Faculty Members

Benjamin Besse, MD, PhD
Institute Gustave Roussy, Villejuif, France

Enriqueta Felip, MD, PhD
Vall d’Hebron University Hospital, Barcelona, Spain

Nasser Hanna, MD
Indiana University School of Medicine, Indianapolis, IN, US

Solange Peters, MD, PhD
University Hospital of Lausanne, Switzerland

Lynette Sholl, MD
Harvard Medical School, Boston, MA, US

David Spigel, MD
Sarah Cannon Research Institute, Nashville, TN, US

David Jablons, MD
University of California, San Francisco, CA, US

Natasha Leighl, BSc, MMSc, MD
Princess Margaret Cancer, Toronto, CA

Sample Report

Start discovering the insights

View Report


  • Immunotherapy in Stage I–III NSCLC
  • Immunotherapy in Metastatic NSCLC and Subsequent Therapy
  • EGFR (Common Mutations): Resectable and Metastatic
  • EGFR (Less Common Mutations, Including Exon 20 Insertions)
  • Other Targets in NSCLC and SCLC

Purchase Report

Thank you for your interest in our insights.

Complete the form below to receive additional information.